Viromed Medical AG Advances with Ex-Vivo Lung Study

Rellingen-based Viromed Medical AG, a pioneer in cold plasma technology, is set to conduct a pivotal ex-vivo lung study in collaboration with Saarland University and Hannover Medical School. Scheduled for early 2025, the study will utilize an isolated lung model that replicates human lung properties with a 95% genetic similarity. This initiative aims to accelerate research and approval processes for Viromed’s technological platform.

The ex-vivo approach presents considerable advantages by eliminating the need for animal and human trials, thus streamlining the research timeline by up to six months. This method is expected to greatly impact preclinical developments by offering substantial reduction in costs and easing regulatory burdens.

The study also highlights Viromed's efforts to advance applications in intensive care and sepsis-related treatments. The approach could potentially expedite the approval process for the company's PulmoPlas® product. Concurrently, Viromed has taken a 35% investment stake in a Saarland University spin-off responsible for this research model.